BiotechTube

Upadacitinib 15 MG [Rinvoq] + Placebo

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Psoriatic Arthritis

Conditions

Psoriatic Arthritis, Spondyloarthritis, Axial

Trial Timeline

Nov 6, 2024 → Dec 1, 2026

NCT ID
NCT06454188

About Upadacitinib 15 MG [Rinvoq] + Placebo

Upadacitinib 15 MG [Rinvoq] + Placebo is a approved stage product being developed by AbbVie for Psoriatic Arthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06454188. Target conditions include Psoriatic Arthritis, Spondyloarthritis, Axial.

What happened to similar drugs?

9 of 20 similar drugs in Psoriatic Arthritis were approved

Approved (9) Terminated (0) Active (11)
✅Ixekizumab + AdalimumabEli LillyApproved
✅TirzepatideEli LillyApproved
✅GuselkumabJohnson & JohnsonApproved
✅methotrexate (MTX) + adalimumab (ADA)AbbVieApproved
✅Secukinumab 300 mg + Secukinumab 150 mgNovartisApproved
✅ApremilastAmgenApproved
✅Apremilast (CC-10004)AmgenApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06454188ApprovedRecruiting

Competing Products

20 competing products in Psoriatic Arthritis

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
41
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
21
Ixekizumab + PlaceboEli LillyPhase 3
40
Ixekizumab + TirzepatideEli LillyPre-clinical
33
Ixekizumab + TirzepatideEli LillyPhase 3
44
Ixekizumab + AdalimumabEli LillyApproved
43
Alefacept + Methotrexate + PlaceboAstellas PharmaPhase 2
35
SUNPG18_07 I (Tildrakizumab 200 mg) + SUNPG18_07 II (Tildrakizumab 100 mg)Sun PharmaceuticalPhase 2/3
38
TILD sub-cutaneous (SC) injectionSun PharmaceuticalPhase 3
44
SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBOSun PharmaceuticalPhase 2
35
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
40
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
44
Ixekizumab + AdalimumabEli LillyPhase 3
44
TirzepatideEli LillyApproved
50
Placebo + Ixekizumab 80 mg Q4W + Ixekizumab 80 mg Q2WEli LillyPhase 3
40
GuselkumabJohnson & JohnsonApproved
50
RSS0393 ointment + RSS0393 ointment + RSS0393 ointment placeboJiangsu Hengrui MedicinePhase 2
42